Home > Riviste > The Journal of Cardiovascular Surgery > Fascicoli precedenti > The Journal of Cardiovascular Surgery 2009 August;50(4) > The Journal of Cardiovascular Surgery 2009 August;50(4):531-4

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

THE JOURNAL OF CARDIOVASCULAR SURGERY

Rivista di Chirurgia Cardiaca, Vascolare e Toracica


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,632


eTOC

 

CASE REPORTS  VASCULAR SECTION


The Journal of Cardiovascular Surgery 2009 August;50(4):531-4

Copyright © 2009 EDIZIONI MINERVA MEDICA

lingua: Inglese

Recombinant activated factor VII for treatment of refractory hemorrhage after surgery for acute aortic dissection

Grubitzsch H. 1, Vargas-Hein O. 2, Von Heymann C. 2, Konertz W. 1

1 Department of Cardiovascular Surgery University of Clinic Charité Campus Charité Mitte, Berlin, Germany
2 Department of Anaesthesiology and Intensive Care Medicine University Clinic Charité Campus Charité Mitte, Berlin, Germany


PDF  


Despite appropriate treatment, surgery for aortic dissection is frequently associated with bleeding problems. In these series we report on the employment of recombinant activated factor VII (rFVIIa) for refractory hemorrhage after emergency surgery for acute type A aortic dissection, used to face the problems of postoperative blood loss and transfusion requirements. Despite the good results of the therapy, a patient presented with thrombosis of the left cavernous sinus. Although a risk of thromboembolic complications has to be considered, rFVIIa is a reasonable rescue option in life-threatening hemorrhage and enlarges our hemostatic armamentarium in surgery for acute aortic dissection.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail